CLYM Climb Bio, Inc.
Healthcare$11.00+0.82%ClosedMarket Cap: $750.0M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
5.07
P/S
0.00
EV/EBITDA
-13.27
DCF Value
$0.49
FCF Yield
-7.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-31.5%
ROA
-34.6%
ROIC
-40.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-15.2M | $-13.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-19.3M | $-17.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-67.9M | $-59.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.9M | $-12.9M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-10.7M | $-8.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-23.0M | $-20.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.9M | $-8.4M | $— | — |
| FY null | $0.00 | NaN% | $-82.0M | $-73.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-11.7M | $-8.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-56.4M | $-54.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.0M | $-1.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-5.1M | $-3.6M | $-0.13 | — |